Trigeminal Neuralgia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies – Noema Pharma AG, Biohaven Pharmaceuticals

October 17 22:15 2022
Trigeminal Neuralgia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Noema Pharma AG, Biohaven Pharmaceuticals
The Trigeminal Neuralgia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Trigeminal Neuralgia pipeline products will significantly revolutionize the Trigeminal Neuralgia market dynamics.

DelveInsight’s “Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Trigeminal Neuralgia, historical and forecasted epidemiology as well as the Trigeminal Neuralgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Trigeminal Neuralgia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Trigeminal Neuralgia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Trigeminal Neuralgia Market Insights

 

Trigeminal Neuralgia Overview

Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition that affects the trigeminal or fifth cranial nerve, one of the most widely distributed nerves in the head. It is a form of neuropathic pain (pain associated with nerve injury or nerve lesion), and categorized in two types: primary (idiopathic) and secondary.

 

Some of the key facts of the Trigeminal Neuralgia Market Report:  

  • The Trigeminal Neuralgia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per the National Organization for Rare Disorders (NORD), trigeminal neuralgia affects females slightly more often than males 
  • A study conducted by Manzoni et al. in Italy stated that trigeminal neuralgia has an incidence ranging from about 4–5 per 100,000 per year up to 20 per 100,000 per year after age 60. The female-to-male ratio is about 3:2 
  • Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, and others 
  • Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, and others 

 

Get a Free sample for the Trigeminal Neuralgia Market Report 

 

Key benefits of the Trigeminal Neuralgia Market report:

  1. Trigeminal Neuralgia market report covers a descriptive overview and comprehensive insight of the Trigeminal Neuralgia Epidemiology and Trigeminal Neuralgia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Trigeminal Neuralgia market report provides insights on the current and emerging therapies.
  3. Trigeminal Neuralgia market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Trigeminal Neuralgia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Trigeminal Neuralgia market.

 

Download the report to understand which factors are driving Trigeminal Neuralgia epidemiology trends @ Trigeminal Neuralgia Epidemiological Insights 

 

Trigeminal Neuralgia Market  

The dynamics of the Trigeminal Neuralgia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

 

“Anticonvulsant drugs, muscle relaxants, and neuroleptic agents are the preferred medical treatment for trigeminal neuralgia. Large placebo-controlled clinical trials are scarce, and no specific established substance has been developed for the treatment of trigeminal neuralgia.” 

 

Trigeminal Neuralgia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Trigeminal Neuralgia Epidemiology Segmentation:

The Trigeminal Neuralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Trigeminal Neuralgia
  • Prevalent Cases of Trigeminal Neuralgia by severity
  • Gender-specific Prevalence of Trigeminal Neuralgia
  • Diagnosed Cases of Episodic and Chronic Trigeminal Neuralgia

 

Trigeminal Neuralgia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Trigeminal Neuralgia market or expected to get launched during the study period. The analysis covers Trigeminal Neuralgia market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Trigeminal Neuralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Trigeminal Neuralgia market share @ Trigeminal Neuralgia market forecast 

 

Trigeminal Neuralgia Therapies and Key Companies

  • Basimglurant: Noema Pharma AG
  • Rimegepant: Biohaven Pharmaceuticals

 

Scope of the Trigeminal Neuralgia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Trigeminal Neuralgia Companies: Noema Pharma AG, Biohaven Pharmaceuticals, and others
  • Key Trigeminal Neuralgia Therapies: Basimglurant, Rimegepant, and others
  • Trigeminal Neuralgia Therapeutic Assessment: Trigeminal Neuralgia current marketed and Trigeminal Neuralgia emerging therapies
  • Trigeminal Neuralgia Market Dynamics:  Trigeminal Neuralgia market drivers and Trigeminal Neuralgia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Trigeminal Neuralgia Unmet Needs, KOL’s views, Analyst’s views, Trigeminal Neuralgia Market Access and Reimbursement 

 

Table of Contents 

1. Trigeminal Neuralgia Market Report Introduction

2. Executive Summary for Trigeminal Neuralgia

3. SWOT analysis of Trigeminal Neuralgia

4. Trigeminal Neuralgia Patient Share (%) Overview at a Glance

5. Trigeminal Neuralgia Market Overview at a Glance

6. Trigeminal Neuralgia Disease Background and Overview

7. Trigeminal Neuralgia Epidemiology and Patient Population

8. Country-Specific Patient Population of Trigeminal Neuralgia 

9. Trigeminal Neuralgia Current Treatment and Medical Practices

10. Trigeminal Neuralgia Unmet Needs

11. Trigeminal Neuralgia Emerging Therapies

12. Trigeminal Neuralgia Market Outlook

13. Country-Wise Trigeminal Neuralgia Market Analysis (2019–2032)

14. Trigeminal Neuralgia Market Access and Reimbursement of Therapies

15. Trigeminal Neuralgia Market Drivers

16. Trigeminal Neuralgia Market Barriers

17.  Trigeminal Neuralgia Appendix

18. Trigeminal Neuralgia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Trigeminal Neuralgia treatment, visit @ Trigeminal Neuralgia Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com